Showing 31-40 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Development of Allosteric G6PC1 Partial Inhibitors | Vanderbilt University | Richard O’Brien | Improving Lives | 01-October-2023 to 31-October-2026 | $549.940,00 |
| Immune-checkpoint engineered beta cells as treatment for T1D | UT Southwestern | Andrew Wang | Cures | 01-October-2023 to 30-September-2026 | $746.818,40 |
| Targeted delivery of therapeutics to islet beta cells for preventing and treating diabetes | UT Southwestern | Juanzhu Yan | Cures | 01-March-2025 to 30-April-2028 | $285.000,00 |
| Modes of action of a beta cell targeted prodrug for preventing and treating type 1 diabetes | UT Southwestern | Wen-hong Li | Cures | 01-November-2025 to 31-October-2028 | $990.000,00 |
| Identifying the temporal functions of beta cell UPR in T1D | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Feyza Engin | Cures | 01-February-2023 to 31-January-2028 | $750.000,00 |
| Single nucleus multiomics temporal profiling of islet immune cells in male and female NOD mice during UPR-deficiency-induced senescence | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Feyza Engin | Cures | 01-February-2025 to 31-January-2028 | $750.000,00 |
| Process development for adipose tissue implantation of immune evasive ES-derived islet-like cells | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Jacques Galipeau | Cures | 01-January-2026 to 31-December-2027 | $628.883,28 |
| Stem Cell-derived Islet Vascularized Extracellular Matrix Organoids for Enhanced Transplantation Success | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Jon Odorico | Cures | 01-January-2024 to 31-December-2026 | $1.394.960,67 |
| ICAM-1 Knock Out Pluripotent Stem Cells for Hypoimmune Type 1 Diabetes Therapy | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Matthew Brown | Cures | 01-April-2025 to 31-March-2027 | $699.998,53 |
| Randomized trial of semaglutide for diabetic kidney disease in type 1 diabetes | University of Washington | Ian De Boer | Improving Lives | 01-September-2023 to 31-March-2028 | $2.107.411,00 |